New Market - November 23, 2015
XVIVO’s product approved in China
XVIVO Perfusion has received approval of its STEEN Solution by the China Food and Drug Administration (CFDA). This decision enables the company to market and sell STEEN Solution for clinical use in China. CFDA has approved STEEN Solution for lung transplantation, which allows sales of STEEN Solution for clinical use in lung transplants in China. […]
MedTech Business - August 13, 2014
Xvivo gets FDA approval for lung perfusion system
The company has received approval from the FDA for the products XPS and STEEN Solution for sale on the American market. The approval, which is the first in the USA for warm perfusion of organs outside the body pending transplantation, means that STEEN Solution, XPS and the accompanying single-use articles are the only medical device […]
Financing - June 27, 2014
Xvivo completes private placement of shares
The board of directors of Xvivo Perfusion AB has resolved to issue 1,950,000 new shares in Xvivo through a private placement directed to a group of qualified Swedish and international investors. The subscription price for each new share was set to SEK 37.50 through a book-building procedure. Through the Private Placement Xvivo raises SEK 73,125,000 before issue costs. The […]
MedTech Business - February 3, 2014
Xvivo expands US study
Barnes Jewish Hospital in St Louis is the tenth transplant center to participate in the Swedish medtech company Xvivo’s NOVEL trial. The NOVEL trial is designed to evaluate the effect of the product Steen Solutions in increasing the amount of usable lungs in the donor pool. The study is being performed at 10 centers in […]
